Last Updated: May 11, 2026

CARDIOGEN-82 Drug Patent Profile

Name: CARDIOGEN-82 Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Cardiogen-82, and when can generic versions of Cardiogen-82 launch?

Cardiogen-82 is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in CARDIOGEN-82 is rubidium chloride rb-82. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rubidium chloride rb-82 profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CARDIOGEN-82?
What are the global sales for CARDIOGEN-82?
What is Average Wholesale Price for CARDIOGEN-82?

Summary for CARDIOGEN-82

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	48
What excipients (inactive ingredients) are in CARDIOGEN-82?	CARDIOGEN-82 excipients list
DailyMed Link:	CARDIOGEN-82 at DailyMed

Drug patent expirations by year for CARDIOGEN-82

Recent Clinical Trials for CARDIOGEN-82

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bracco Diagnostics, Inc

See all CARDIOGEN-82 clinical trials

Pharmacology for CARDIOGEN-82

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for CARDIOGEN-82

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CARDIOGEN-82

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989	4,400,358	⤷ Start Trial
Bracco	CARDIOGEN-82	rubidium chloride rb-82	INJECTABLE;INJECTION	019414-001	Dec 29, 1989	4,562,829	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CARDIOGEN-82

See the table below for patents covering CARDIOGEN-82 around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	7135281		⤷ Start Trial
Japan	S60241454	STORONTIUM-RUBIDIUM INJECTION SYSTEM	⤷ Start Trial
Japan	2568169		⤷ Start Trial
Australia	548918		⤷ Start Trial
Ireland	811361		⤷ Start Trial
European Patent Office	0310148		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.